Safety and Effectiveness of Experimental IMC-F106C for Advanced PRAME-Positive Cancers
a study on Solid Tumor
Select Advanced Solid Tumors ImmTAC Immunotherapy Bispecific T cell receptor fusion protein Immune mobilizing monoclonal T cell receptor against cancer Checkpoint inhibitor PD1 / PD-1 PD-L1 / PDL1 IMC-F106C anti-PD(L)1
Lead Scientist at UC Davis
- Hui Amy Chen, MD
Assistant Professor, Obstetrics and Gynecology.